Pharmacogenetics and psychiatry

被引：6

作者：

Basu A. ^{[1
]}

Tsapakis E. ^{[1
]}

Aitchison K. ^{[1
]}

机构：

[1] Social Genet./Devmtl. Psychiat. Ctr., Institute of Psychiatry, London SE5 8AF, 1 Windsor Walk, Denmark Hill

来源：

Current Psychiatry Reports | 2004年 / 6卷 / 2期

关键词：

Clozapine; Olanzapine; Fluvoxamine; Tardive Dyskinesia; Variable Number Tandem Repeat;

D O I：

10.1007/s11920-004-0053-5

中图分类号：

学科分类号：

摘要：

Genetic factors play a significant role in predicting an individual's response to a drug. The response may be the desired therapeutic effect of the drug and also may be the undesirable development of adverse effects. This relationship between genes and drug response interests the pharmacogeneticist. This article aims to give an overview of the exciting discoveries made so far in the field of psychiatry, particularly concerning the response to antidepressants and antipsychotics, as well as to mention some of the more recent findings. The ultimate goal of pharmacogenetics is to provide medication "tailored" to the individual based on their genetic profile, and although this may currently seem a distant target, it has already begun to raise ethical questions, which also are discussed. Copyright © 2004 by Current Science Inc.

引用

页码：134 / 142

页数：8

共 54 条

[1] Aitchison K.J., Gonzalez F.J., Quattrochi L.C., Et al., Identification of novel polymorphisms in the 5′ flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance, Pharmacogenetics, 10, pp. 695-704, (2000)
[2] Aitchison K.J., Gill M., Pharmacogenetics in the postgenomic era, Behavioral Genetics in the Postgenomic Era, pp. 335-361, (2003)
[3] Kane J.M., Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview, Br. J. Psychiatry, 17, SUPPL., pp. 41-45, (1992)
[4] Aitchison K.J., Jann M.W., Zhao J.H., Et al., Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice, J. Psychopharmacol., 14, pp. 353-359, (2000)
[5] Kalow W., Tang B.-K., Use of caffeine metabolic ratios to explore CYP1A2 and xanthine oxidase activities, Clin. Pharmacol. Ther., 50, pp. 508-519, (1991)
[6] Arranz M.J., Munro J., Birkett J., Et al., Pharmacogenetic prediction of clozapine response, Lancet, 355, pp. 1615-1616, (2000)
[7] Schumacher J., Schulze T.G., Wienker T.F., Et al., Pharmacogenetics of clozapine response, Lancet, 356, pp. 506-507, (2000)
[8] Yu Y.W., Tsai S.J., Yang K.H., Et al., Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine, Neuropsychobiology, 43, pp. 79-82, (2001)
[9] Atkin K., Kendall F., Gould D., Et al., Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland, Br. J. Psychiatry, 169, pp. 483-488, (1996)
[10] Corrigan F.M., MacDonald S., Reynolds G.P., Clozapine-induced hypersalivation and the alpha 2 adrenoceptor, Br. J. Psychiatry, 167, (1995)

← 1 2 3 4 5 6 →